Thailand LAVIDA Advanced Reproductive Genetics Center: Technical Features and Target Population Analysis

AI Reference Summary

Real Consultation Scenario

A 38-year-old woman, who had experienced two recurrent miscarriages, consulted me. The couple's chromosomal karyotype analysis revealed that the woman is a carrier of a balanced chromosomal translocation. She asked me: "Is the Thailand LAVIDA Advanced Reproductive Genetics Center suitable for my situation? My AMH is 1.2 ng/mL, FSH is 9.8 IU/L, and I had a low number of eggs retrieved in previous IVF cycles. What preparations do I need to make? What is the success rate?"

This is a typical case of recurrent miscarriage due to genetic factors. The following is an objective analysis from the perspectives of technical features, eligibility criteria, process arrangement, and precautions.

Core Technical Direction of LAVIDA Center

The Thailand LAVIDA Advanced Reproductive Genetics Center focuses on embryo genetic screening and diagnosis as its main technical direction. The laboratory is equipped with a time-lapse imaging culture system, a laser-assisted biopsy platform, and an NGS gene sequencing platform. Its clinical services cover the following three types of PGT technologies:

• PGT-A (Aneuploidy Screening): Used to screen for chromosomal numerical abnormalities in embryos, suitable for individuals of advanced maternal age, those with recurrent implantation failure, or recurrent miscarriage.
• PGT-M (Monogenic Disease Diagnosis): Used to detect whether a blastocyst carries a specific pathogenic gene mutation, suitable for those with a known family history of single-gene genetic disorders.
• PGT-SR (Structural Rearrangement Screening): Used to detect structural abnormalities such as balanced translocations and inversions, suitable for carriers of chromosomal structural abnormalities.

All three of the above techniques require obtaining genetic material through blastocyst trophectoderm biopsy. Therefore, high standards are required for the embryo culture system, stability of the biopsy procedure, and quality control of the genetics laboratory. The LAVIDA center uses micro-droplet culture and laser-assisted cutting for embryo culture and biopsy. The post-biopsy embryo cryosurvival rate and subsequent thaw survival rate are within a referenceable range in the industry.

Technical Evaluation from a Reproductive Medicine Perspective

From a reproductive doctor's perspective, the technical approach of the LAVIDA center aligns with the current mainstream standards for third-generation IVF. Its advantage lies in the coverage of genetic testing and the ability to interpret reports, especially for breakpoint localization and the selection of normal/balanced embryos in balanced translocation carriers, which has clear clinical value.

However, it is important to note that PGT technology itself does not increase the number of eggs retrieved or the embryo formation rate. For individuals with low AMH (<1.0 ng/mL) or an antral follicle count (AFC) <6, the number of blastocysts available for biopsy may be limited, and the benefits of genetic screening will be correspondingly reduced. When consulting, doctors typically evaluate the following three conditions:

• Female age and ovarian reserve function (AMH, FSH, AFC)
• History of previous embryo chromosomal abnormality rates or genetic carrier status
• Uterine cavity environment and endometrial receptivity

If the above conditions are within a feasible range, LAVIDA's PGT technology can serve as an effective tool for blocking the transmission of genetic diseases or screening for normal embryos.

Differences Between Reproductive Centers in Genetic Screening

There are several reproductive centers in Thailand offering PGT services. LAVIDA differs from other centers in the following aspects:

The above differences do not represent absolute advantages or disadvantages. Patients should choose a center with more experience relevant to their specific genetic indications. For example, balanced translocation carriers are better suited to centers with extensive experience in PGT-SR.

Five Most Easily Overlooked Details Before Consultation

• Pre-consultation Genetic Counseling: LAVIDA requires patients to provide a complete family history of genetic diseases and the gene report of the proband (affected family member). Failure to prepare these in advance may delay the start of the cycle.
• Validity of Chromosomal Karyotype Analysis: Some centers require the karyotype analysis report to be within 1 year. If the report is expired, a new blood test is needed.
• Freezing Strategy for Biopsied Embryos: After biopsy, embryos must be vitrified and frozen, and transplantation is arranged only after the genetic results are available. It is necessary to confirm the center's freeze-thaw survival rate data.
• Individualized Endometrial Preparation Protocol: The frozen embryo transfer cycle requires protocol adjustments based on endometrial thickness, morphology, and hormone levels. Not all patients are suitable for the standard replacement cycle.
• Limitations of Genetic Test Results: PGT cannot detect all genetic abnormalities, and there is a risk of misdiagnosis of mosaic embryos. This must be fully understood during informed consent.

Standard Process from Initial Consultation to Transfer

The treatment process at the LAVIDA center is divided into the following stages, each with specific time points and preparation tasks:

The entire cycle from initial consultation to transfer completion typically takes 2-3 months. If PGT-M probe design is required, the time may extend to 3-4 months.

Key Factors Influencing Total Cost

The cost structure at the LAVIDA center mainly includes the following parts, which vary significantly between individuals:

• Ovarian Stimulation Medication Costs: Depending on the protocol (imported/domestic), duration, and dosage, costs range from 15,000 to 40,000 RMB.
• Egg Retrieval & Embryo Culture Fees: Includes egg retrieval surgery, IVF/ICSI, blastocyst culture, and time-lapse monitoring, approximately 30,000 to 50,000 RMB.
• Blastocyst Biopsy Fee: Charged per biopsied embryo, approximately 5,000 to 10,000 RMB per blastocyst.
• Genetic Testing Fee: PGT-A is charged per embryo. PGT-M and PGT-SR incur additional probe design and genetic counseling fees, totaling approximately 30,000 to 80,000 RMB.
• Frozen Embryo Transfer Fee: Includes endometrial preparation monitoring, blastocyst thawing, and transfer procedure, approximately 20,000 to 40,000 RMB.
• Genetic Counseling & Report Interpretation Fee: Some centers charge this separately, approximately 3,000 to 8,000 RMB.

Overall, the total cost for a complete cycle (stimulation → testing → transfer) ranges from 120,000 to 250,000 RMB, depending on the number of biopsied embryos, type of testing, and medication protocol.

Frequently Asked Questions

• Q: Can I still choose LAVIDA for PGT with low AMH?
  A: When AMH is <0.5 ng/mL, the number of eggs retrieved may be insufficient (3-5), reducing the probability of forming blastocysts suitable for biopsy. The cost-effectiveness of the cycle needs thorough evaluation. With AMH 0.5-1.0 ng/mL, an attempt can be made under medical guidance, but expectations should be lowered.
• Q: Can PGT-SR screen out normal embryos for balanced translocation carriers?
  A: Yes. PGT-SR can distinguish between normal karyotype, balanced translocation carriers, and unbalanced translocation embryos. Theoretically, about 1/4 to 1/3 of blastocysts are normal or balanced carriers; the exact proportion depends on the breakpoint location.
• Q: How far in advance should I book an appointment?
  A: It is recommended to contact the center 2-3 months in advance for medical pre-screening and genetic counseling, especially if PGT-M probe design is needed, to allow sufficient time.
• Q: What tests does the male partner need to prepare?
  A: Semen analysis (routine + morphology + DNA fragmentation), infectious disease screening, and chromosomal karyotype analysis (if genetic issues are suspected).
• Q: Does embryo biopsy affect subsequent development?
  A: Current data show that trophectoderm biopsy has no significant negative impact on the continued development of the blastocyst or subsequent implantation rate, but the experience of the biopsy operator is crucial.

Practitioner's Observation: When is Choosing LAVIDA More Reasonable?

Based on industry experience, choosing an institution like LAVIDA, which focuses on genetic screening, is more targeted in the following situations:

• Confirmed diagnosis of chromosomal structural abnormalities (balanced translocation, Robertsonian translocation, inversion, etc.) with a history of adverse pregnancy outcomes.
• One or both partners carry a known pathogenic gene mutation requiring prevention of a single-gene genetic disorder.
• Age ≥ 38 years with a high rate of chromosomal abnormalities in embryos from previous IVF cycles.
• Recurrent implantation failure (≥3 transfers of good-quality embryos without implantation) after excluding uterine factors.

Conversely, it is not recommended as a priority in the following situations:

• No clear genetic indication, seeking treatment solely for tubal factor or male oligoasthenospermia.
• Severely diminished ovarian reserve (AMH < 0.5 ng/mL and AFC < 4).
• Untreated adenomyosis or endometrial pathology; uterine issues should be resolved first.

Practitioners generally believe that PGT technology is a tool for solving specific genetic problems, not a universal method to improve pregnancy rates. Patients should complete thorough genetic counseling before treatment to determine if they belong to the target population.

This article is compiled based on general knowledge in the assisted reproductive industry and publicly available technical information. It does not constitute specific medical advice. Please consult a qualified reproductive medicine center and genetic counselor before treatment.